Journal of Hepatocellular Carcinoma最新文献

{"title":"NRF1-Induced lncRNA DDX11-AS1 Contributes to the Progression of Hepatocellular Carcinoma via Activating CA9 Expression and the MEK/ERK Pathway.","authors":"Yingnan Li, Mengjiao Shi, Beibei Bie, Hongwei Tian, Jun Li, Zongfang Li, Jin Sun","doi":"10.2147/JHC.S516656","DOIUrl":"https://doi.org/10.2147/JHC.S516656","url":null,"abstract":"<p><strong>Purpose: </strong>DDX11 antisense RNA 1 (DDX11-AS1) has been recognized for its strong correlation with hepatocellular carcinoma (HCC). Nevertheless, the exact biological functions and fundamental molecular processes of DDX11-AS1 in HCC require further in-depth investigation.</p><p><strong>Methods: </strong>A comprehensive bioinformatics analysis was carried out to explore the expression of DDX11-AS1 and its clinical implication in HCC utilizing the TCGA data. qRT-PCR was employed to validate the expression of DDX11-AS1 in HCC tissues/cell lines. RNA fluorescence in situ hybridization (RNA-FISH) was used to observe the subcellular localization of DDX11-AS1 in HCC cells. Loss-of-function experiments, both in vitro and in vivo, were executed to elucidate the biological functions of DDX11-AS1 in HCC. RNA sequencing (RNA-seq) was employed to identify genes and signaling pathways potentially regulated by DDX11-AS1. Rescue experiments were conducted to validate that carbonic anhydrase IX (CA9) mediates DDX11-AS1 promoting HCC progression. The influence of nuclear respiratory factor 1 (NRF1) on the transcription of DDX11-AS1 was investigated through dual-luciferase reporter assays and ChIP-qPCR.</p><p><strong>Results: </strong>The increased expression of DDX11-AS1 is positively associated with several aggressive clinical characteristics (pathologic T stage, histologic grade, AFP level, and vascular invasion), and is closely linked to unfavorable outcomes in HCC patients, acting as a separate hazardous factor for overall survival. DDX11-AS1 is predominantly situated in the nucleus of HCC cells. DDX11-AS1 knockdown impeded the growth, migration, and invasion capabilities of HCC cells in vitro, and reduced the tumor enlargement in a subcutaneous mouse model. RNA-Seq unveiled that silencing DDX11-AS1 lessened the expression of CA9 and suppressed the activity of the MEK/ERK signaling cascade in HCC cells. Rescue experiments uncovered that CA9 acts as a downstream target facilitating the cancer-causing roles of DDX11-AS1 in HCC. Furthermore, DDX11-AS1 was revealed to be transcriptionally regulated by NRF1.</p><p><strong>Conclusion: </strong>DDX11-AS1, a NRF1-induced lncRNA, facilitates HCC development by upregulating CA9 expression and activating the MEK/ERK signaling cascade.</p>","PeriodicalId":15906,"journal":{"name":"Journal of Hepatocellular Carcinoma","volume":"12 ","pages":"891-908"},"PeriodicalIF":4.2,"publicationDate":"2025-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12067462/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143969928","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness of Minimally Invasive Hepatectomy in Patients with Early or Intermediate-Stage Hepatocellular Carcinoma: A Multi-Institutional Cohort Study in an Asian Population.","authors":"Hung-Kai Chen, Kai-Cheng Chang, Shih-Chieh Shao, Ruey-Shyang Soong, Yi-Chan Chen, Chun-Feng Wu, Tsung-Han Wu, Tien-Shin Chou, Siu-Cheung Chan, Edward Chia-Cheng Lai","doi":"10.2147/JHC.S485171","DOIUrl":"https://doi.org/10.2147/JHC.S485171","url":null,"abstract":"<p><strong>Purpose: </strong>Minimally invasive hepatectomy (MIH) has been increasingly applied for patients with hepatocellular carcinoma (HCC). However, the effectiveness of MIH has yet to be well established.</p><p><strong>Patients and methods: </strong>This retrospective cohort study included patients aged 20 years and older, newly receiving MIH for HCC with Barcelona Clinic Liver Cancer (BCLC) classification stage 0, A or B from 2010 to 2019. Two 1:1 propensity score-matched cohorts of those receiving open hepatectomy (OH) and those receiving radiofrequency ablation (RFA) were selected as comparison groups. As a control analysis, we compared patients receiving OH with those receiving RFA under the hypothesis that the OH group had better survival outcomes than the RFA group.</p><p><strong>Results: </strong>We included a total of 555 matched patients receiving MIH or OH, and 382 matched patients receiving MIH or RFA. Compared to the OH group, MIH group was associated with better overall survival (OS) (Hazard ratios (HR): 0.62; 95% CI: 0.43-0.88) and similar PFS (HR: 0.92; 0.74-1.16). Compared to the RFA group, we found the MIH group was associated with better OS (0.46; 0.32-0.67) and better PFS (0.48; 0.38-0.61). We found consistent results from a series of subgroup analyses (eg, age groups, BCLC stages and hospital levels) and sensitivity analyses (eg, study period restricted to the most recent 5 years (2015-2019)). The control analysis (OH group vs RFA group) confirmed the robustness of main analyses.</p><p><strong>Conclusion: </strong>Our study suggested that MIH had better survival outcomes for patients with early or resectable intermediate-stage HCC, compared to RFA or OH.</p>","PeriodicalId":15906,"journal":{"name":"Journal of Hepatocellular Carcinoma","volume":"12 ","pages":"879-890"},"PeriodicalIF":4.2,"publicationDate":"2025-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12067648/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143974678","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Post-TACE ALBI-Score Trajectory in Intermediate and Advanced Hepatocellular Carcinoma: Prognostic Implications and Influencing Factors Analysis.","authors":"Jian Li, Tianyuyi Feng, Chi Cui, Haochen Wang, Tianhao Su, Long Jin, Xiaohu Zhao, Weizhong Xiao","doi":"10.2147/JHC.S503581","DOIUrl":"https://doi.org/10.2147/JHC.S503581","url":null,"abstract":"<p><strong>Objective: </strong>The long-term effects of transarterial chemoembolization (TACE) on liver function and their prognostic implications in hepatocellular carcinoma (HCC) have not been fully explored. The Albumin-Bilirubin (ALBI) score, an objective measure of liver function, is a validated prognostic tool in HCC. This study aims to characterize the longitudinal trajectories of ALBI-scores after TACE, evaluate their impact on clinical outcomes, and identify factors influencing these trajectories.</p><p><strong>Materials and methods: </strong>This retrospective study included patients with BCLC stage B/C HCC who underwent TACE, with baseline and at least two post-TACE ALBI-score measurements. Group-Based Trajectory Modeling (GBTM) was used to identify distinct ALBI-score trajectories. Clinical outcomes and patient characteristics were compared across trajectory groups. A CatBoost-based clinical prediction model was developed to identify factors influencing ALBI-score trajectories, with Shapley Additive Explanations (SHAP) values providing feature importance interpretation.</p><p><strong>Results: </strong>Among 501 patients, three ALBI-score trajectories were identified: improve, stable, and decline. The improve group had better overall survival (OS) and progression-free survival (PFS) compared to the stable and decline groups. Multivariate analysis confirmed that ALBI-score trajectories were independent risk factors for OS. Subgroup analysis suggested that TACE plus systemic therapy reduced mortality risk in the stable and decline groups. The CatBoost model effectively distinguished distinct trajectory groups, with SHAP analysis highlighting ALBI-grade, Child-Pugh class, and tumor number as key predictors.</p><p><strong>Conclusion: </strong>Post-TACE ALBI-score trajectories are closely linked to clinical outcomes, with improved liver function associated with better prognosis. Monitoring these trajectories could guide personalized treatment strategies for HCC patients undergoing TACE.</p>","PeriodicalId":15906,"journal":{"name":"Journal of Hepatocellular Carcinoma","volume":"12 ","pages":"865-878"},"PeriodicalIF":4.2,"publicationDate":"2025-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12063622/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144011102","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic Significance of Elevated Platelet Count (>200 x 10^9 per L) in BCLC Stages B and C of Hepatocellular Carcinoma: A Retrospective Multicenter Analysis.","authors":"Stefan Munker, Isaac Rodriguez, Kathrin Bernhart, Najib Ben Khaled, Merve Findik, Lisa Katrin Siegmund, Liangtao Ye, Florian P Reiter, Daniel Roessler, Daniel Nasseh, Lorenz Balcar, Katharina Pomej, Bernhard Scheiner, Christel Weiss, Matthias Pinter, Max Seidensticker, Julia Mayerle, Alexander B Philipp, Enrico N De Toni","doi":"10.2147/JHC.S511263","DOIUrl":"https://doi.org/10.2147/JHC.S511263","url":null,"abstract":"<p><strong>Introduction: </strong>In hepatocellular carcinoma (HCC) comorbidities related to decreased liver function or to portal hypertension often limit treatment options. Traditionally, low platelet count has been considered a negative prognostic factor in HCC, especially in early stages. However, recent evidence suggests that elevated platelet count may also predict worse outcomes in advanced stages, suggesting a stage-dependent prognostic impact.</p><p><strong>Aim: </strong>This study evaluated the prognostic role of platelet counts across BCLC stages, adjusted for portal hypertension, to improve individualized patient management.</p><p><strong>Methods: </strong>In this retrospective, multicenter study, platelet count of 1112 patients with HCC in different tumor stages was analyzed. Various platelet count cutoffs (X to Y × 10^9/L) were tested to identify the optimal prognostic threshold. To isolate the effect of platelet levels from portal hypertension, spleen diameter was incorporated as an adjustment variable in multivariate analyses, with variceal status considered when available (in about two thirds of patients). Using an optimized cut-off, survival analysis was performed using univariate and multivariate Cox proportional hazards models. Bootstrapping was performed for internal validation.</p><p><strong>Results: </strong>Platelet count outside 84-200 × 10^9/L was associated with poorer survival (HR = 0.66, 95% CI = 0.57-0.78, p < 0.0001). Bootstrapping showed robustness of the final model. Subgroup analysis revealed worse survival in BCLC stages B and C but not stage A for elevated platelet counts (>200 × 10^9/L) in multivariate analysis (including spleen diameter).</p><p><strong>Conclusion: </strong>Platelet counts showed a stage-dependent prognostic impact in HCC. A platelet count above a cutoff of 200/µL at diagnosis was associated with poorer prognosis. Using this cutoff may improve survival prediction in BCLC B and C patients with potential usage for risk stratification and guidance of treatment decisions. Further external validation is required to confirm these findings and evaluate their clinical applicability.</p>","PeriodicalId":15906,"journal":{"name":"Journal of Hepatocellular Carcinoma","volume":"12 ","pages":"855-864"},"PeriodicalIF":4.2,"publicationDate":"2025-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12063624/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143983236","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Synergistic Mechanisms and Prospects of Transarterial Chemoembolization Combined with Immunotherapy for Hepatocellular Carcinoma.","authors":"Qi-Feng Chen, Song Chen, Ming Zhao","doi":"10.2147/JHC.S514881","DOIUrl":"https://doi.org/10.2147/JHC.S514881","url":null,"abstract":"<p><p>Hepatocellular carcinoma (HCC) represents a highly aggressive form of liver neoplasm that presents various therapeutic obstacles. Recently, the synergistic use of transarterial chemoembolization (TACE) in conjunction with immunotherapy has attracted considerable interest within the medical community. This review aims to explore the synergistic mechanisms between TACE and immunotherapy, analyze the current research evidence, and discuss their potential applications in the treatment of HCC. By examining how TACE can enhance the efficacy of immunotherapy, we seek to provide direction for future research and emphasize the importance of personalized treatment strategies in managing HCC.</p>","PeriodicalId":15906,"journal":{"name":"Journal of Hepatocellular Carcinoma","volume":"12 ","pages":"841-854"},"PeriodicalIF":4.2,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12050036/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144006157","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hepatic Arterial Infusion Chemotherapy for Hepatocellular Carcinoma: A Three-Dimensional Visualization Perspective.","authors":"Yong Tan, Ping-Ping Li, Hui Liu, Jian-Yong Zhu, Qing-Song Wu","doi":"10.2147/JHC.S513695","DOIUrl":"https://doi.org/10.2147/JHC.S513695","url":null,"abstract":"<p><p>In Asia, hepatic arterial infusion chemotherapy is an alternative therapeutic option for hepatocellular carcinoma (HCC). However, the current application of HAIC lacks precision, as drug dosages are typically calculated based solely on body surface area. This approach often results in underdosing for patients with larger liver tumors or greater liver volume and overdosing for those with smaller liver tumors or reduced liver volume. Consequently, determining drug dosages according to the specific target volume requiring treatment may enhance individualized and standardized therapy for HCC, aligning with the principles of precision oncology.</p>","PeriodicalId":15906,"journal":{"name":"Journal of Hepatocellular Carcinoma","volume":"12 ","pages":"837-840"},"PeriodicalIF":4.2,"publicationDate":"2025-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12047304/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144022361","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Impact of Microwave Ablation on Recurrence and Metastasis of Hepatocellular Carcinoma: Insights From Animal Studies and Cytokine Profiling.","authors":"Yujia Wang, Hongtong Tan, Chunyong Wen, Shuanggang Chen, Guanglei Zheng, Han Qi, Lin Xie, Lujun Shen, Fei Cao, Weijun Fan","doi":"10.2147/JHC.S515779","DOIUrl":"https://doi.org/10.2147/JHC.S515779","url":null,"abstract":"<p><strong>Background: </strong>Microwave ablation (MWA) is commonly used to treat hepatocellular carcinoma (HCC), but its effects on normal liver tissue and tumors remain unclear. While MWA causes direct tumor destruction, it also induces inflammatory responses in the surrounding liver tissue, which may influence tumor progression, metastasis, and recurrence. The role of cytokine alterations in this post-ablation inflammatory microenvironment is crucial for understanding how MWA impacts tumor behavior.</p><p><strong>Purpose: </strong>This study aims to investigate the impact of post-ablation inflammatory responses on HCC recurrence and metastasis through animal experiments and cytokine profiling, with the goal of identifying potential biomarkers or therapeutic targets.</p><p><strong>Materials and methods: </strong>This study involved 35 male C57BL/6 mice (6-8 weeks old) to establish metastatic and orthotopic cancer models. The effects of normal liver tissue ablation and HCC ablation on tumor metastasis and recurrence were investigated. Cytokine expression changes were assessed using the Proteome Profiler Mouse XL Cytokine Array, and prognostic implications were analyzed using the TCGA database. Multiple group comparisons assessed using the Mann-Whitney <i>U</i>-test. Statistical significance was defined as a two-tailed p-value less than 0.05.</p><p><strong>Results: </strong>Microwave ablation of normal liver tissue promotes intrahepatic metastasis of HCC. Incomplete ablation of liver tumors accelerates intrahepatic or pulmonary metastasis. Post-ablation, increased expression of MMP-9, OPN, VEGF, CHI3L1, AREG, CXCL2, and IL-1α in the peritumoral region suggests a shift toward a pro-inflammatory and pro-metastatic microenvironment, potentially facilitating tumor cell invasion, angiogenesis, and immune evasion.</p><p><strong>Conclusion: </strong>HCC recurrence and metastasis following ablation may be driven by cytokine-mediated changes in the tumor microenvironment. Targeting key cytokines such as MMP-9, OPN, and CHI3L1 could provide new strategies for improving post-ablation outcomes and reducing recurrence rates in clinical settings.</p>","PeriodicalId":15906,"journal":{"name":"Journal of Hepatocellular Carcinoma","volume":"12 ","pages":"825-835"},"PeriodicalIF":4.2,"publicationDate":"2025-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12042830/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144024472","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Atezolizumab Plus Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma: Real-World Experience From a US Community Oncology Network.","authors":"David Cosgrove, Ruoding Tan, Andrew J Osterland, Sairy Hernandez, Sarika Ogale, Sami Mahrus, John Murphy, Thomas Wilson, Gregory Patton, Arturo Loaiza-Bonilla, Amit G Singal","doi":"10.2147/JHC.S492881","DOIUrl":"https://doi.org/10.2147/JHC.S492881","url":null,"abstract":"<p><strong>Purpose: </strong>Atezolizumab plus bevacizumab (atezo-bev) is a preferred first-line (1L) systemic therapy option for unresectable hepatocellular carcinoma (uHCC). However, evidence of its effectiveness in real-world clinical practice, including in patients with impaired liver function, remains limited.</p><p><strong>Patients and methods: </strong>This retrospective observational study included adult patients who initiated 1L atezo-bev for uHCC within The US Oncology Network between 1/1/2019 and 8/31/2022 using structured and unstructured electronic health records data. Overall survival (OS) and real-world progression-free survival (rwPFS) were assessed using Kaplan-Meier methods for the overall cohort and in a subgroup of \"trial-like\" patients with characteristics that were consistent with those of the IMbrave150 Trial (ECOG performance status 0-1, Child-Pugh class A, albumin-bilirubin grade 1-2).</p><p><strong>Results: </strong>Overall, 374 patients met eligibility criteria (mean age 68.8 years, 78.9% male, 31% Child-Pugh class B-C among reported, 18% ECOG performance status ≥2 among reported), of whom 132 patients comprised the trial-like subgroup. At a median follow-up of 5.6 months, median (95% CI) OS was 13.2 (9.5, 15.9) months and rwPFS was 6.4 (5.1, 7.7) months. In the trial-like subgroup, median (95% CI) OS was 16.5 (13.2, NR) months and rwPFS was 9.4 (5.7, 12.5) months.</p><p><strong>Conclusion: </strong>Atezo-bev was used as 1L systemic therapy for HCC in a diverse patient population across US community oncology settings. Real-world effectiveness of atezo-bev among trial-like patients is comparable to that reported in the Phase 3 study. These data can help guide selection of appropriate treatment candidates and maximize the benefits of atezo-bev in routine clinical practice.</p>","PeriodicalId":15906,"journal":{"name":"Journal of Hepatocellular Carcinoma","volume":"12 ","pages":"791-804"},"PeriodicalIF":4.2,"publicationDate":"2025-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12015733/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144004672","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Novel Prognostic Signature Integrating Immune and Glycolytic Pathways for Enhanced Prognosis and Immunotherapy Prediction in Hepatocellular Carcinoma.","authors":"Zeyu Zhang, Hongxi Zhao, Pengyu Wang, Xueyan Geng, Maopeng Yin, Yingjie Liu, Shoucai Zhang, Yongyuan Liang, Jian Ji, Guixi Zheng","doi":"10.2147/JHC.S510460","DOIUrl":"https://doi.org/10.2147/JHC.S510460","url":null,"abstract":"<p><strong>Background: </strong>This study aimed to establish an immune-glycolysis-related prognostic signature (IGRPS) to predict hepatocellular carcinoma (HCC) outcomes. Additionally, it explored the role of this signature in the tumor immune microenvironment (TIME), glycolytic pathways, and immunotherapy.</p><p><strong>Methods: </strong>We analyzed RNA-seq, single-cell sequencing, and immune- and glycolysis-related gene datasets from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO). Using weighted gene co-expression network analysis (WGCNA), F-test, and Cox regression, we identified key survival-related immune and glycolytic genes (SRIGRGs) and developed an IGRPS through multivariate Cox regression. The IGRPS's predictive performance was validated in training and validation cohorts using Kaplan-Meier survival analysis, receiver operating characteristic (ROC) curves, and a prognostic nomogram. Its correlation with TIME and its ability to predict immunotherapy outcomes were also assessed. In vitro experiments were conducted to analyze the expression and function of IGRPS genes in HCC.</p><p><strong>Results: </strong>Thirteen SRIGRGs were identified for constructing the IGRPS. Patients with low-risk scores had significantly longer survival times. The area under the curve (AUC) for ROC curves was over 0.73 for training and 0.7 for validation cohorts, with C-indices of 0.721 and 0.79, respectively. IGRPS was confirmed as an independent prognostic indicator. Patients in the low-risk group showed better responses to combined anti-CTLA4 and anti-PD-1 therapies. In vitro experiments indicated that PRKAG1 and B3GAT3 were upregulated, enhancing glycolysis and promoting HCC cell proliferation and migration.</p><p><strong>Conclusion: </strong>The IGRPS, based on immune- and glycolysis-related genes, effectively predicted prognosis and immunotherapy responses in HCC patients.</p>","PeriodicalId":15906,"journal":{"name":"Journal of Hepatocellular Carcinoma","volume":"12 ","pages":"805-823"},"PeriodicalIF":4.2,"publicationDate":"2025-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12013648/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144024337","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Novel Nomogram Model for Predicting the Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Infection.","authors":"Yanfang Wu, Meixia Wang, Zhenzhen Zhang, Guobin Chen, Boheng Zhang","doi":"10.2147/JHC.S512471","DOIUrl":"https://doi.org/10.2147/JHC.S512471","url":null,"abstract":"<p><strong>Purpose: </strong>Hepatitis B virus (HBV) infection is a major cause of hepatocellular carcinoma (HCC). This study aimed to construct a novel nomogram model for predicting the risk of HCC in patients with HBV infection.</p><p><strong>Patients and methods: </strong>This retrospective study analyzed clinical data from healthcare databases in Xiamen, encompassing 5161 adults with HBV infection without HCC and 2819 adults with HBV-related HCC between January 2016 and December 2020. Subsequently, the patients were randomly divided into a training set (n=5586) and testing set (n=2394). The training set was used to identify the risk factors for HCC development and to construct an HCC risk prediction nomogram model. The predictive accuracy of the model was assessed using the receiver operating characteristic (ROC) curve analysis and decision curve analysis (DCA) in both sets. Furthermore, the performance of the nomogram model was compared with that of the existing models.</p><p><strong>Results: </strong>Multivariate analysis revealed that age, sex, liver cirrhosis, neutrophil/platelet count ratio (NLR), serum bilirubin (TBIL), aspartate aminotransferase (AST), serum albumin (ALB), serum alpha-fetoprotein (AFP), and HBV DNA were independently associated with HCC. A nomogram model was developed by incorporating these risk factors. The the receiver operating characteristic curve (AUC) of the nomogram model were 0.897 and 0.902 for the training and testing sets, respectively. Analysis of the AUC demonstrated that the nomogram model exhibited significantly enhanced predictive performance for HCC compared to the alternative risk scores in both sets. Furthermore, DCA indicated that the nomogram model provided a broad range of threshold probabilities related to the net clinical benefits. A web-based calculator was developed(https://nomogram-model-hcc.shinyapps.io/DynNomapp/).</p><p><strong>Conclusion: </strong>The novel nomogram model, which includes age, sex, liver cirrhosis, NLR, TBIL, AST, ALB, AFP, and HBV DNA as factors, precisely predicts the risk of HCC in patients with chronic hepatitis B(CHB) and outperforms the existing models.</p>","PeriodicalId":15906,"journal":{"name":"Journal of Hepatocellular Carcinoma","volume":"12 ","pages":"765-775"},"PeriodicalIF":4.2,"publicationDate":"2025-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12009588/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144024973","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}